{"id":"W3120912770","doi":"10.1093/ofid/ofaa439.1221","title":"1035. Patient-Reported Outcomes on Long-Acting Cabotegravir + Rilpivirine as Maintenance Therapy: FLAIR 96-Week Results","year":2020,"lang":"en","type":"article","venue":"Open Forum Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"GlaxoSmithKline (Canada); University Health Network","funders":"","keywords":"Rilpivirine; Medicine; Abacavir; Dolutegravir; Randomized controlled trial; Human immunodeficiency virus (HIV); Internal medicine; Lamivudine; Antiretroviral therapy; Viral load; Family medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00364145,0.0005856139,0.001075733,0.0003045819,0.0003230011,0.0005721023,0.0004274417,0.0007010518,0.007137114],"category_scores_gemma":[0.00202514,0.0001658771,0.001455903,0.0002789071,0.0002612835,0.0006965569,0.0004409641,0.0009645885,0.0009211865],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003608715,"about_ca_system_score_gemma":0.000419784,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009956487,"about_ca_topic_score_gemma":0.001142601,"domain_scores_codex":[0.9981792,0.001060186,0.0001531821,0.0001982282,0.0002147345,0.0001945408],"domain_scores_gemma":[0.9982947,0.0003937318,0.0006132406,0.0001311137,0.0001854139,0.0003818952],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7503554,0.01369326,0.07327177,0.0005142561,0.002040384,0.00007663903,0.0002334519,0.00134153,0.007353854,0.0001285551,0.004579709,0.1464112],"study_design_scores_gemma":[0.08527134,0.4130188,0.4848714,0.0001350792,0.002394238,0.0002422067,0.0002485418,0.00340292,0.005026017,0.0001798001,0.005090444,0.0001192752],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9928188,0.0007876836,0.000293495,0.0001480678,0.00003491375,0.0003849755,0.003145695,0.00005143302,0.002334901],"genre_scores_gemma":[0.9948827,0.0001125125,0.000561451,0.0001615428,0.00005038176,0.0004189075,0.002446046,0.000006853581,0.00135968],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007137114,"threshold_uncertainty_score":0.02387607,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0276448731580631,"score_gpt":0.2947878649152534,"score_spread":0.2671429917571904,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}